A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

GLP-1 drugs were originally intended to control their blood sugar. Since then, they’ve shown promise in countering cardiovascular disease, hypertension, Parkinson disease, and substance use ...

With GLP-1 shortage issue largely resolved, continued growth in this category is expected, although direct-to-consumer channels may complicate efforts to track usage trends. Overall U.S. drug ...

Background Recent research on Parkinson's disease (PD) therapy has highlighted glucagon-like peptide 1 (GLP-1) agonists as potential therapeutic agents. However, recent randomized controlled trials ...

People who followed the MIND diet -- a combination of the Mediterranean diet and the Dietary Approaches to Stop Hypertension ...

An estimated 1.1 million people in the United States are living with Parkinson's disease, a progressive brain disorder characterized by tremors, slowness of movement, limb stiffness, and gait and ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... of medicine at the University of California San Francisco’s regional campus in Fresno, said this latest research bolsters ...

These side effects may include: GLP-1 agonists are approved for people with type 2 diabetes to manage their blood sugar levels, and some are approved for weight loss. Let’s take a look at the ...

According to the Parkinson’s Foundation, approximately 1.1 million people in America are living with Parkinson’s disease, making it the second most common neurodegenerative disorder after ...

“Living within 1 mile of a golf course was associated with 126% increased odds of PD compared with those living farther than 6 miles away from a golf course.” The risk of Parkinson’s disease ...